On Wednesday, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s shares inclined 3.23% to $50.49.
Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently declared the appointment of Jacques Dumas, Ph.D. as Chief Scientific Officer.
Dr. Dumas joins Tetraphase from Merck Research Laboratories where he served as Vice President, Idenix, related to his preceding role as Chief Scientific Officer at Idenix Pharmaceuticals. From 2007 to 2014, Jacques worked for AstraZeneca, most recently as Vice President and Head of Strategy, Infection Innovative Medicines. In this role, he was responsible for disease area strategy and external collaborations for AstraZeneca’s small molecule infectious disease unit. Preceding to AstraZeneca, Jacques worked at Bayer Healthcare for 15 years, most recently as Director of Medicinal Chemistry. Jacques received his Ph.D. in Organic Chemistry from Paris IV University in France and accomplished a Postdoctoral Fellowship at Stanford University.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multi-drug resistant infections. Its lead product candidate comprises eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, counting multidrug-resistant Gram-negative infections.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s shares dropped -1.04% to $11.40.
Ironwood Pharmaceuticals, Inc. (IRWD) declared the pricing of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2022 (the Notes). The Notes are being offered and sold to qualified institutional buyers following Rule 144A under the Securities Act of 1933, as amended. Ironwood has also granted the initial purchasers of the Notes an option to purchase up to an additional $45 million aggregate principal amount of the Notes solely to cover over-allotments.
The Notes will bear cash interest at a rate of 2.25%, payable on June 15 and December 15 of each year, starting on December 15, 2015. The Notes will not be redeemable prior to maturity. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Ironwood Class A common stock, or a combination of cash and shares of Ironwood’s Class A common stock, at Ironwood’s election. The initial conversion rate for the Notes is 60.3209 shares of Ironwood’s Class A common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of about $16.58 per share of Ironwood’s Class A common stock, representing an about 35% conversion premium based on the last stated sale price of Ironwood’s Class A common stock of $12.28 per share on June 9, 2015.
Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has partnershipagreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, in addition to in China, Hong Kong, and Macau.
At the end of Wednesday’s trade, National Penn Bancshares (NASDAQ:NPBC)‘s shares surged 0.09% to $11.47.
National Penn Bancshares, Inc. ( NPBC) declared that it plans to release its 2nd Quarter 2015 earnings on Thursday, July 23, 2015 preceding to market opening. A conference call with analysts will be broadcast live over the Internet at 10:00 a.m. Eastern Daylight Time that day.
The conference call and webcast will feature a brief talk aboution of National Penn Bancshares, Inc.’s financial results, followed by a question and answer session with analysts. National Penn Bancshares, Inc. presenters will be Scott V. Fainor, president and chief executive officer; Michael J. Hughes, chief financial officer; and Sandra L. Bodnyk, chief risk officer.
National Penn Bancshares, Inc. operates as the bank holding company for National Penn Bank that provides commercial banking products, primarily deposits and loans to residents and businesses primarily in eastern and central Pennsylvania. Its deposit products comprise demand, NOW, money market, other checking and savings accounts, and certificates of deposit. The company also offers consumer loan products, counting installment loans, home equity loans, residential mortgage loans, educational loans, and credit cards; commercial loans comprising short-term loans for seasonal and working capital purposes, term loans secured by real estate and other assets, loans for construction and expansion needs, and revolving credit facilities; and commercial real estate lending services compriseing of loans to developers of residential and commercial projects.
Aerie Pharmaceuticals Inc (NASDAQ:AERI), ended its Wednesday’s trading session with -1.47% loss, and closed at $19.47.
Aerie Pharmaceuticals, Inc. (AERI) a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, declared that Julie McHugh and Michael M. du Toit have been elected to the Company’s Board of Directors. Both individuals bring extensive senior healthcare-focused leadership experience, Ms. McHugh from large pharmaceutical and biotechnology firms and Mr. du Toit in media and marketing. Their elections are effective right away, bringing the total number of Aerie’s Board members to nine.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates comprise Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has accomplished Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.